After decades of intensive research, a groundbreaking treatment for Alzheimer's disease has arrived. In July 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla® (donanemab), an innovative immunotherapy that represents a significant step forward in the fight against this devastating condition. This marks the dawn of disease-modifying treatments that target the biological causes of Alzheimer's rather than just managing symptoms. What Makes Kisunla® Revolutionary

For years, the fear surrounding Alzheimer’s disease has felt like a genetic lottery—if you carry the wrong gene, the risk seems...

When thinking of heart failure, most of us imagine weakened hearts and trouble breathing—not lunch menus or frailty. But recent research...

Osteoporosis is a common bone disease that weakens bones, making them more likely to break—especially in postmenopausal women and men...